Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nuvo Research Announces Lawsuit Against Mallinckrodt
http://www.pharmpro.com/news/2013/08/nuvo-research-announces-lawsuit-against-mallinckrodt
Nuvo Research® announces that FDA has accepted Pennsaid® 2% new drug application for review
http://online.wsj.com/article/PR-CO-20130822-905209.html
light the fuse, could happen anytime, no one to miss the boom
couldn't agree more
Gums The Insider Buying Is Impressive...unbelievable really, looks like the whole board loaded up on shares in the spring. makes a person wonder what is to come. can't see them loading for no reason. they would know best, jmo
pecking away at .75's, will be interesting if this will break through that wall today
nice volume 400k so far
great volume
biospecialist,
how do you think these new shares will impact the stock and are we almost through them do you think? thanks for you imput
So maybe they pulled their order, interesting to see from my stand point anyway, I like it when it goes up and there is large bid presence fake or real, it's real to me
funny how when that not real order shows up on the bid the price goes up, that must be not real as well
somebody wants in bad, seemingly
120,000 bid @ .59 , $72000 on the bid, interesting
BINGO . . . these sites don't just sell anyone's product either, there is alot of dd put in before that takes place imo
Thank you, should be interesting
Aren't they due out a financial report soon? anyone know?
nice bid support all of a sudden, could be interesting
I hold some and will be holding long, this company has so much potential weather it be in their innovative drugs or their new possibly ground breaking delivery system that may be able to be brokered out to all pharmaceutical companies going foward, who knows, should be interesting, jmo.
It looks like it could break out at any time with a touch of volume
pSivida CEO to Present at 15th Annual BioCEO & Investor Conference February 12
56 minutes ago - BusinessWire via Comtex
pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), an emerging specialty pharmaceutical company and leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr. Paul Ashton, will present at the 15th Annual BioCEO & Investor Conference, being held at the Waldorf-Astoria Hotel in New York, Monday and Tuesday, February 11 and 12. Dr. Ashton will make his presentation on Tuesday, February 12 at 1 p.m. EST. A webcast of the presentation will be available at: http://www.veracast.com/webcasts/bio/ceoinvestor2013/19217378.cfm or at the company's website: www.psivida.com. There will be a webcast replay available one hour after the conclusion of Dr. Ashton's presentation that day and it will be available until May 12, 2013.
About pSivida Corp.
pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drugs designed to be released at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert(TM) and BioSilicon(TM). Two FDA-approved products, Vitrasert(TM) and Retisert(TM) are licensed to Bausch & Lomb. The company has licensed ILUVIEN(R) for DME to Alimera Sciences and that product has received marketing authorization in Austria, France, Germany, Portugal, Spain and the UK. pSivida has clinical trials ongoing for the treatment of posterior uveitis and glaucoma and hypertension. Other technologies under development by pSivida include protein and antibody delivery systems in early clinical stages.
SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: uncertainties with respect to: Alimera's ability to finance, achieve additional marketing approvals, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the EU; outcome of reimbursement for ILUVIEN in the U.K., Alimera's resubmission of its NDA for ILUVIEN for DME and its ability to obtain regulatory approval for, and if approved, to finance, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the U.S.; financing and success of Phase III posterior uveitis trials including efficacy, side effects and risk/benefit profile of the posterior uveitis micro-insert; initiation, financing and success of Latanoprost Product Phase II trials and exercise by Pfizer of its option; development of products using Tethadur and BioSilicon; initiation and completion of clinical trials and obtaining regulatory approval of product candidates; adverse side effects; ability to attain profitability; ability to obtain additional capital; further impairment of intangible assets; fluctuations in operating results; decline in royalty revenues; ability to, and to find partners to, develop and market products; termination of license agreements; competition and other developments affecting sales of products; market acceptance; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution; possible influence by Pfizer; absence of dividends; and other factors described in our filings with the SEC. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20130204006128r1&sid=cmtx4&distro=nx
SOURCE: pSivida
Agreed
PSDV
Highest EPS Growth in the Life Sciences Tools & Services Industry Detected for pSivida (PSDV, TMO, CBM)
1 hours 28 minutes ago - Financial News Network Online - News Corner via Comtex
Below are the three companies in the Life Sciences Tools & Services industry with the highest year-over-year expected earnings per share (EPS) growth rates. pSivida (NASDAQ:PSDV) is highest with EPS growth of 546.2%. pSivida Corporation is a drug delivery company. The Company develops products utilizing its own technologies for targeted and controlled drug delivery. pSivida's products are mainly used in ophthalmology and oncology healthcare sectors. Thus far today, pSivida has traded 19,000 shares, vs. average volume of 62,000 shares per day. The stock has outperformed the Dow (3.0% to the Dow's -0.5%) and outperformed the S&P 500 (3.0% to the S&P's -0.6%) during today's trading.
PSDV
Highest EPS Growth in the Life Sciences Tools & Services Industry Detected for pSivida (PSDV, TMO, CBM)
1 hours 28 minutes ago - Financial News Network Online - News Corner via Comtex
Below are the three companies in the Life Sciences Tools & Services industry with the highest year-over-year expected earnings per share (EPS) growth rates. pSivida (NASDAQ:PSDV) is highest with EPS growth of 546.2%. pSivida Corporation is a drug delivery company. The Company develops products utilizing its own technologies for targeted and controlled drug delivery. pSivida's products are mainly used in ophthalmology and oncology healthcare sectors. Thus far today, pSivida has traded 19,000 shares, vs. average volume of 62,000 shares per day. The stock has outperformed the Dow (3.0% to the Dow's -0.5%) and outperformed the S&P 500 (3.0% to the S&P's -0.6%) during today's trading.
PSDV
Highest EPS Growth in the Life Sciences Tools & Services Industry Detected for pSivida (PSDV, TMO, CBM)
1 hours 28 minutes ago - Financial News Network Online - News Corner via Comtex
Below are the three companies in the Life Sciences Tools & Services industry with the highest year-over-year expected earnings per share (EPS) growth rates. pSivida (NASDAQ:PSDV) is highest with EPS growth of 546.2%. pSivida Corporation is a drug delivery company. The Company develops products utilizing its own technologies for targeted and controlled drug delivery. pSivida's products are mainly used in ophthalmology and oncology healthcare sectors. Thus far today, pSivida has traded 19,000 shares, vs. average volume of 62,000 shares per day. The stock has outperformed the Dow (3.0% to the Dow's -0.5%) and outperformed the S&P 500 (3.0% to the S&P's -0.6%) during today's trading.
Highest EPS Growth in the Life Sciences Tools & Services Industry Detected for pSivida (PSDV, TMO, CBM)
1 hours 28 minutes ago - Financial News Network Online - News Corner via Comtex
Below are the three companies in the Life Sciences Tools & Services industry with the highest year-over-year expected earnings per share (EPS) growth rates. pSivida (NASDAQ:PSDV) is highest with EPS growth of 546.2%. pSivida Corporation is a drug delivery company. The Company develops products utilizing its own technologies for targeted and controlled drug delivery. pSivida's products are mainly used in ophthalmology and oncology healthcare sectors. Thus far today, pSivida has traded 19,000 shares, vs. average volume of 62,000 shares per day. The stock has outperformed the Dow (3.0% to the Dow's -0.5%) and outperformed the S&P 500 (3.0% to the S&P's -0.6%) during today's trading.
45,000 shares on the bid.... $135,000 they want in
30,000 shares on bid @ 3.07 somebody wants in here, we could see a nice power hour
FWIW I saw more commercials for the sonic and the mustang this weekend watching the NCAA tourney than any other vehicles, maybe we get something unexpected sometime soon, here's to hoping
Not sure anyone believes that at all, most know the reality and whats ahead, numbers and industrial release but I will say this it's getting old, originally we were told January for the industrial release and here we sit. your motives are suspect though.
AGREED
MAYBE ITs going down because of the notes selling, until that is over we sit imo
AGREED, WE ARE GETTING CLOSER IMO
GOOD SIGN TO ME 2 INSIDERS LOCKING DOWN ROUGHLY 50 MILLION shares JMO soon enough she should pop a bit
Looks like we got a new big shareholder as they own 17,100,000 shares.
I think you are correct and it is coming soon, why else would someone spend roughly $10,000 buying over 2 million shares this morning at the ask, if it was shorters covering why not just sit the bid and let everyone dump to you after yesterday's filing?
JMO
My guess is on that day, Tuesday release. jmo